HcG peptide (human chorionic gonadotropin) is a complex heterodimeric glycoprotein research compound widely investigated for its high-affinity agonist activity at the luteinizing hormone/choriogonadotropin receptor (LHCGR). In laboratory settings, researchers utilize high-purity hCG peptide to evaluate steroidogenesis pathways, gonadal receptor signaling kinetics, and cell differentiation cascades in both in vitro assays and preclinical animal models.
HcG peptide (human chorionic gonadotropin) is a complex heterodimeric glycoprotein research compound widely investigated for its high-affinity agonist activity at the luteinizing hormone/choriogonadotropin receptor (LHCGR). In laboratory settings, researchers utilize high-purity hCG peptide to evaluate steroidogenesis pathways, gonadal receptor signaling kinetics, and cell differentiation cascades in both in vitro assays and preclinical animal models.
HcG peptide is a complex, heterodimeric glycoprotein comprising two non-covalently linked subunits designated as alpha (α) and beta (β). The common alpha subunit consists of 92 amino acids and shares sequence identity with other pituitary glycoprotein hormones, including luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). The unique beta subunit consists of 145 amino acids and imparts specific biological activity and binding selectivity toward the shared luteinizing hormone/choriogonadotropin receptor (LHCGR).
The intact dimeric structure has an approximate molecular mass of 36.7 kDa, with oligosaccharide side chains accounting for roughly 30% of the total molecular weight. These heavy N- and O-linked glycosylations directly influence the peptide's tertiary conformation, receptor affinity, and metabolic half-life in laboratory models. When evaluated in experimental setups, maintaining the structural integrity of both subunits is critical, as subunit dissociation renders the peptide biologically inactive at the LHCGR target site. For comparative studies evaluating gonadotropin release upstream, researchers often cross-reference hypothalamic peptides within our comprehensive research catalog.
The primary mechanism of action for hCG peptide centers on its high-affinity binding to LHCGR, a classical G-protein coupled receptor (GPCR) expressed predominantly on testicular Leydig cells and ovarian granulosa/theca cells. Binding of the beta-subunit region to the extracellular domain of LHCGR triggers a conformational change that activates heterotrimeric G-proteins, specifically the Gs subunit. This event stimulates membrane-bound adenyl cyclase, driving a rapid rise in intracellular cyclic adenosine monophosphate (cAMP).
Elevated cAMP levels activate Protein Kinase A (PKA), initiating a phosphorylation cascade that transcriptionally upregulates key steroidogenic enzymes and transport proteins. Prominent among these is the Steroidogenic Acute Regulatory (StAR) protein, which facilitates the rate-limiting transfer of cholesterol across the outer mitochondrial membrane to the inner mitochondrial membrane. Subsequent enzymatic processing by cytochrome P450 side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, establishing the foundational pathway for downstream androgen and estrogen synthesis in preclinical model systems. Further details on GPCR signaling networks are documented in the PX1 research library.
In cell culture and isolated tissue preparations, hCG peptide serves as a benchmark ligand for evaluating Leydig cell functionality and steroidogenic capacity. Primary rodent Leydig cell cultures and immortalized Leydig cell lines (such as MA-10 and TM3) are frequently exposed to controlled concentration gradients of hCG peptide to measure real-time cAMP accumulation and testosterone biosyntheses. These assays allow researchers to probe receptor desensitization, downregulation pathways, and intracellular feedback mechanisms under defined physiological variables.
In vivo rodent models utilize research-grade hCG peptide to examine intratesticular vascularization, Leydig cell proliferation, and local steroid concentrations following gonadotropic stimulation. Because hCG peptide binds LHCGR with significantly higher affinity and exhibits a longer biological half-life than endogenous LH, it remains an indispensable tool for comparative pharmacology studies investigating gonadotropin-dependent pathways.
Beyond testicular models, hCG peptide is extensively utilized in female reproductive biology research to model follicular maturation, cumulus expansion, and luteinization. In cultured ovarian granulosa and theca cells, hCG peptide exposure initiates the expression of genes responsible for progesterone synthesis, matrix metalloproteinases, and vascular endothelial growth factor (VEGF), mimicking the preovulatory LH surge in vitro.
Preclinical rodent and non-human primate tissue models utilize hCG peptide to investigate the signaling cascades required for corpus luteum formation and maintenance. These experimental setups help map the differential activation of the MAPK/ERK and PI3K/Akt pathways downstream of LHCGR engagement, providing valuable insight into cellular survival, apoptosis regulation, and vascular remodeling in luteal tissue.
When designing protocols to investigate the hypothalamic-pituitary-gonadal (HPG) axis, researchers often contrast the direct receptor agonism of hCG peptide against upstream peptide modulators. While hCG peptide acts directly as a peripheral agonist at the gonadal LHCGR target, hypothalamic releasing factors operate upstream at the pituitary level to stimulate endogenous LH and FSH secretion.
For instance, decapeptides like gonadorelin and potent analogues like triptorelin stimulate pituitary GnRH receptors, resulting in pulsatile or desensitizing release of endogenous gonadotropins. Similarly, upstream regulators such as kisspeptin-10 act on hypothalamic KiSS1 receptors to control GnRH release upstream of the pituitary. In contrast, research protocols employing hCG peptide bypass the hypothalamic-pituitary architecture entirely, providing a direct, quantifiable signal exclusively at the peripheral gonadal receptor site.
Due to its complex quaternary structure and extensive glycosylation, hCG peptide requires careful reconstitution and handling to preserve molecular stability and prevent denaturation. Lyophilized hCG peptide should be brought to room temperature in a desiccated environment prior to opening the vial to prevent condensation from introducing moisture to the cake.
Reconstitution should be performed using an appropriate laboratory diluent, such as sterile bacteriostatic water (containing 0.9% benzyl alcohol) for multi-use analytical protocols or sterile phosphate-buffered saline (PBS, pH 7.4) for immediate cell culture applications. The diluent should be introduced gently along the glass vial wall rather than sprayed directly onto the lyophilized powder. The vial should be gently swirled or rolled between the palms until full dissolution occurs. High-shear force mechanical agitation, such as aggressive vortexing, must be strictly avoided as it induces protein foaming and structural denaturation of the heterodimer.
Lyophilized hCG peptide exhibits excellent stability when stored at temperatures between -20°C and -80°C in a dry, dark environment protected from light exposure. Under these conditions, the unconstituted peptide maintains structural integrity and biological potency for extended periods.
Once reconstituted into aqueous solution, hCG peptide becomes significantly more susceptible to enzymatic cleavage, aggregation, and hydrolysis. Reconstituted stock solutions should be divided into single-use analytical aliquots to avoid repeated freeze-thaw cycles, which severely degrade heterodimeric stability. Short-term storage of reconstituted liquid stock should be maintained at 2°C to 8°C for no more than 14 to 28 days depending on the preservative used, while aliquoted working stocks intended for long-term usage must be frozen at -80°C.
High-rigor laboratory research requires strict verification of compound purity, identity, and biological safety standards. Every lot of hCG peptide provided by PX1 Research undergoes rigorous analytical testing, beginning with Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity standards exceeding 98.0%. RP-HPLC confirms the absence of truncated beta-chain fragments, free alpha-subunits, or processing impurities.
Identity verification is confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry, ensuring the precise molecular weight matches theoretical values. Furthermore, because bacterial endotoxins can confound cell culture viability and provoke non-specific inflammatory signaling in preclinical models, all lots undergo chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels strictly below <0.01 EU/mg.
PX1 Research supplies USA-manufactured research peptides designed specifically for demanding laboratory applications, cellular assays, and preclinical research protocols. Every product lot is independently audited by ISO 17025 accredited laboratories, with full third-party Certificates of Analysis (COAs) detailing HPLC chromatograms, mass spectra, and endotoxin assay results available for complete lot traceability.
Orders are fulfilled directly from our modern, temperature-controlled distribution centers in California and Arizona, offering same-day dispatch (Monday through Friday) to ensure cold-chain integrity and rapid delivery to academic, clinical, and industrial research institutions. Laboratories managing high-throughput screening projects or large-scale preclinical cohorts can establish dedicated account channels through our wholesale peptide program.
What is the primary target receptor for hCG peptide in research models?
HcG peptide functions as a direct, high-affinity agonist at the luteinizing hormone/choriogonadotropin receptor (LHCGR), a G-protein coupled receptor expressed on testicular Leydig cells and ovarian granulosa/theca cells.
How does hCG peptide differ structurally from endogenous Luteinizing Hormone (LH)?
While both share an identical 92-amino-acid alpha subunit, hCG peptide possesses a distinct 145-amino-acid beta subunit with a unique C-terminal extension containing additional O-linked oligosaccharide chains, granting higher receptor binding affinity and a significantly longer half-life.
What diluent should be used to reconstitute hCG peptide for laboratory assays?
For analytical assays and short-term laboratory protocols, sterile bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4) is typically used. Diluent choice depends on cell culture toxicity requirements and protocol length.
Why is vortexing discouraged during the reconstitution of hCG peptide?
As a complex heterodimeric glycoprotein, hCG peptide is sensitive to mechanical shear stress. High-shear vortexing causes foaming, surface denaturation, and dissociation of the alpha and beta subunits, rendering the peptide inactive.
How should reconstituted hCG peptide stock solutions be stored?
Reconstituted liquid solutions should be divided into single-use laboratory aliquots to avoid freeze-thaw cycles and stored at -80°C for long-term preservation, or at 2°C to 8°C for short-term use up to 14–28 days depending on the preservative.
What purity levels are confirmed on the PX1 Research COA for hCG peptide?
PX1 Research provides lot-specific Certificates of Analysis confirming peptide purity of ≥98.0% via RP-HPLC, correct identity via ESI-MS, and endotoxin levels tested below <0.01 EU/mg.
What assays are typically used to measure hCG peptide activity in vitro?
Researchers commonly utilize competitive homogeneous time-resolved fluorescence (HTRF) cAMP assays, StAR protein Western blots, and quantitative ELISA assays for downstream steroid (e.g., testosterone, progesterone) biosynthesis.
Where does PX1 Research manufacture and ship its research peptides?
All PX1 Research peptides are manufactured in USA-based, GMP-compliant facilities and shipped directly from fulfillment hubs in California and Arizona with same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.